Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Not Confirmed
Not Confirmed
08-10 October, 2024
Discovery on TargetDiscovery on Target
Not Confirmed
Not Confirmed
30 September-03 October, 2024
Not Confirmed
Not Confirmed
30 September-02 October, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Not Confirmed
08-10 October, 2024
Discovery on TargetDiscovery on Target
Industry Trade Show
Not Confirmed
30 September-03 October, 2024
Industry Trade Show
Not Confirmed
30 September-02 October, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/ice-is-pioneering-sustainability-innovation-in-bile-acid-research-for-neurodegenerative-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/2024-us-elections-harris-trump-differ-on-abortion-rights-aca-public-health-spends-agree-on-need-to-cut-drug-prices
28 Jun 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/06/28/2695973/0/en/Neuronascent-to-Present-New-Parkinson-s-Model-Data-at-AAIC-2023-for-the-Alzheimer-s-Disease-Investigational-Therapy-NNI-362.html
08 Nov 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/11/08/2550583/0/en/Neuronascent-to-Present-Further-NNI-362-Phase1a-Data-at-CTAD-2022-for-Alzheimer-s-Disease.html
01 Jun 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/06/01/2453975/0/en/Neuronascent-Receives-FDA-Orphan-Drug-Designation-for-NNI-351-Treatment-of-Fragile-X-Syndrome.html
24 May 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/05/24/2449058/0/en/Neuronascent-Receives-FDA-Rare-Pediatric-Drug-Designation-for-NNI-351-Treatment-for-Fragile-X-Syndrome.html
30 Mar 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/03/30/2412617/0/en/Neuronascent-Releases-Further-Positive-Results-of-NNI-362-in-A-Randomized-Phase-1a-Trial-for-Alzheimer-s-Disease.html
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?